Parisi, Lorenzo; Fuhrer, Reto; Zinkernagel, Martin; Enzmann, Volker (2019). Ranibizumab and Bevacizumab but Not Aflibercept Inhibit Proliferation of Primary Human Retinal Pigment Epithelium in vitro. Ophthalmologica, 241(3), pp. 137-142. Karger 10.1159/000490430
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
000490430.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (375kB) | Request a copy |
AIM
Treatment of exudative age-related macular degeneration by using vascular endothelial growth factor (VEGF) antagonists is the gold standard today. So far, several bioactive molecules have been approved for therapeutic use. In this study, we investigate the effects of ranibizumab (Lucentis®), bevacizumab (Avastin®), and aflibercept (Eylea®) on primary human retinal pigment epithelial (hRPE) cells in vitro.
METHODS
hRPE cells were prepared from donor eyes and cultured under standard culture conditions. Scleral fibroblasts also prepared from donor tissue served as physiological controls. The impact of the anti-VEGF molecules on cell viability was investigated with the trypan blue exclusion assay, whereas proliferation was measured using the MTT assay. Biological activity of the molecules was quantified in a VEGF-enzyme-linked immunosorbent assay (ELISA).
RESULTS
All tested substances were biologically active in vitro. They displayed no cytotoxicity on RPE cells or scleral fibroblasts. However, proliferation of RPE cells was significantly decreased after treatment with ranibizumab or bevacizumab but not with aflibercept.
CONCLUSIONS
The humanized antibodies (fragments) interfered specifically with the RPE cells. The thereby measured inhibition of cell proliferation may indicate possible side effects on the physiology of RPE cells.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Ophthalmology 04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Augenklinik > Forschungsgruppe Augenheilkunde |
UniBE Contributor: |
Zinkernagel, Martin Sebastian, Enzmann, Volker |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0030-3755 |
Publisher: |
Karger |
Language: |
English |
Submitter: |
Volker Enzmann |
Date Deposited: |
01 Feb 2019 10:38 |
Last Modified: |
20 Sep 2023 15:03 |
Publisher DOI: |
10.1159/000490430 |
PubMed ID: |
30001546 |
Uncontrolled Keywords: |
Aflibercept Bevacizumab Primary human RPE in vitro Proliferation Ranibizumab Scleral fibroblasts Viability |
BORIS DOI: |
10.48350/123424 |
URI: |
https://boris.unibe.ch/id/eprint/123424 |
Actions (login required)
 |
Edit item |